Blocking a migraine signal before pain escalates
CGRP, short for calcitonin gene-related peptide, is a molecule involved in transmitting pain signals. During migraine attacks, CGRP activity is associated with pain and with changes in how nerves and blood vessels communicate. The story is more complicated than a single protein widening blood vessels: migraine is a nervous-system disorder, and CGRP is one important part of its signaling network.
Erenumab is a monoclonal antibody—a lab-made protein designed to bind a particular target. It attaches to the receptor that CGRP would otherwise activate. By making that receptor unavailable, erenumab can reduce CGRP signaling and lower the likelihood of attacks. It is a preventive treatment, not a rescue medicine that stops an attack already underway.
A targeted approach, not a shutdown switch
Other migraine-preventing antibodies bind CGRP itself rather than its receptor. Both strategies aim to interrupt the same pathway, but neither disables the whole nervous system or guarantees that migraines will disappear. These medicines are generally given by injection on a regular schedule; their purpose is to reduce attack frequency, not to treat every possible migraine symptom in the same way.
The approach grew from evidence that CGRP signaling matters in migraine, offering a treatment target more specific to the disorder than many older preventive medicines. Those older drugs were often developed for other conditions and later found useful for some people with migraine. Targeting CGRP gives clinicians another option when choosing prevention, though response varies and treatment decisions depend on a person's health and circumstances.
The practical consequence is a shift from trying to suppress migraine indirectly to interrupting a pathway implicated in attacks—while leaving the rest of the brain's signaling machinery intact.
